These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 7720083

  • 21. Induction of anti-gp160 cytotoxic T cells cross-reacting with various V3 loop P18 peptides in human immunodeficiency virus type 1 envelope-immunized individuals.
    Achour A, Bex F, Hermans P, Burny A, Zagury D.
    J Virol; 1996 Oct; 70(10):6741-50. PubMed ID: 8794311
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM, McKeating JA, de Souza JB, Roitt IM, Delves PJ, Lund T.
    Virology; 1998 Nov 10; 251(1):59-70. PubMed ID: 9813203
    [Abstract] [Full Text] [Related]

  • 24. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L, Schirmbeck R, Reimann J, Wolf H, Wagner R.
    Virology; 1997 Aug 18; 235(1):26-39. PubMed ID: 9300034
    [Abstract] [Full Text] [Related]

  • 25. Design of a complete synthetic peptide-based AIDS vaccine with a built-in adjuvant.
    Nardelli B, Defoort JP, Huang W, Tam JP.
    AIDS Res Hum Retroviruses; 1992 Aug 18; 8(8):1405-7. PubMed ID: 1466968
    [No Abstract] [Full Text] [Related]

  • 26. In vivo induction of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes and delayed-type hypersensitivity by a 23-amino acid peptide from the highly conserved region in major core protein p24.
    Nishino Y, Kameoka M, Okada Y, Zhong Q, Kimura T, Azuma I, Ikuta K.
    Vaccine; 1994 May 18; 12(6):485-91. PubMed ID: 7913566
    [Abstract] [Full Text] [Related]

  • 27. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative.
    Bartlett JA, Wasserman SS, Hicks CB, Dodge RT, Weinhold KJ, Tacket CO, Ketter N, Wittek AE, Palker TJ, Haynes BF.
    AIDS; 1998 Jul 30; 12(11):1291-300. PubMed ID: 9708408
    [Abstract] [Full Text] [Related]

  • 28. Envelope protein and p18(IIIB) peptide recognized by cytotoxic T lymphocytes from humans immunized with human immunodeficiency virus envelope.
    Achour A, Picard O, Mbika JP, Willer A, Snart R, Bizzini B, Carelli C, Burny A, Zagury D.
    Vaccine; 1993 Jul 30; 11(7):609-701. PubMed ID: 7688170
    [Abstract] [Full Text] [Related]

  • 29. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF, Nichols WG, Palker TJ.
    J Immunol; 1996 Jul 01; 157(1):462-72. PubMed ID: 8683152
    [Abstract] [Full Text] [Related]

  • 30. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
    Keefer MC, Graham BS, McElrath MJ, Matthews TJ, Stablein DM, Corey L, Wright PF, Lawrence D, Fast PE, Weinhold K, Hsieh RH, Chernoff D, Dekker C, Dolin R.
    AIDS Res Hum Retroviruses; 1996 May 20; 12(8):683-93. PubMed ID: 8744579
    [Abstract] [Full Text] [Related]

  • 31. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype.
    McNicholl JM, Bond KB, Ruhadze ER, Olsen MR, Takayama K, Hunter RL.
    AIDS Res Hum Retroviruses; 1998 Nov 01; 14(16):1457-71. PubMed ID: 9824324
    [Abstract] [Full Text] [Related]

  • 32. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.
    Salmon-Céron D, Excler JL, Finkielsztejn L, Autran B, Gluckman JC, Sicard D, Matthews TJ, Meignier B, Valentin C, El Habib R, Blondeau C, Raux M, Moog C, Tartaglia J, Chong P, Klein M, Milcamps B, Heshmati F, Plotkin S.
    AIDS Res Hum Retroviruses; 1999 May 01; 15(7):633-45. PubMed ID: 10331442
    [Abstract] [Full Text] [Related]

  • 33. The multi-epitope polypeptide approach in HIV-1 vaccine development.
    Cano CA.
    Genet Anal; 1999 Nov 01; 15(3-5):149-53. PubMed ID: 10596755
    [Abstract] [Full Text] [Related]

  • 34. Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells.
    Takahashi H, Nakagawa Y, Yokomuro K, Berzofsky JA.
    Int Immunol; 1993 Aug 01; 5(8):849-57. PubMed ID: 8398980
    [Abstract] [Full Text] [Related]

  • 35. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens.
    Schirmbeck R, Deml L, Melber K, Wolf H, Wagner R, Reimann J.
    Vaccine; 1995 Jun 01; 13(9):857-65. PubMed ID: 7483809
    [Abstract] [Full Text] [Related]

  • 36. Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization.
    Ahlers JD, Dunlop N, Pendleton CD, Newman M, Nara PL, Berzofsky JA.
    AIDS Res Hum Retroviruses; 1996 Mar 01; 12(4):259-72. PubMed ID: 8906986
    [Abstract] [Full Text] [Related]

  • 37. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD, Pendleton CD, Dunlop N, Minassian A, Nara PL, Berzofsky JA.
    J Immunol; 1993 Jun 15; 150(12):5647-65. PubMed ID: 8515081
    [Abstract] [Full Text] [Related]

  • 38. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.
    Letvin NL, Robinson S, Rohne D, Axthelm MK, Fanton JW, Bilska M, Palker TJ, Liao HX, Haynes BF, Montefiori DC.
    J Virol; 2001 May 15; 75(9):4165-75. PubMed ID: 11287566
    [Abstract] [Full Text] [Related]

  • 39. Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens.
    Conley AJ, Conard P, Bondy S, Dolan CA, Hannah J, Leanza WJ, Marburg S, Rivetna M, Rusiecki VK, Sugg EE.
    Vaccine; 1994 Apr 15; 12(5):445-51. PubMed ID: 8023553
    [Abstract] [Full Text] [Related]

  • 40. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.
    Belyakov IM, Wyatt LS, Ahlers JD, Earl P, Pendleton CD, Kelsall BL, Strober W, Moss B, Berzofsky JA.
    J Virol; 1998 Oct 15; 72(10):8264-72. PubMed ID: 9733870
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.